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Mohammad Abdollahi*DARU Journal of Pharmaceutical Sciences (DARU) is
one of the 47 scientific journals of Tehran University of
Medical Sciences (TUMS). When the journal was
launched in 1991, articles were published in the Persian
language; English abstracts were then added in 1995,
and finally it completed the transition to publishing in
the English language for both abstracts and full-text in
early 1999.
The main scope of this journal is to serve as a
platform for all areas of drug conception, design,
manufacturing, classification and assessment. DARU
welcomes outstanding studies from basic research to
clinical investigations as original papers, systematic
reviews, meta-analyses, general reviews, mini-reviews,
short communications, and editorials from the global
scientific community.
DARU considers guidelines provided by International
Committee of Medical Journal Editors (www.icmje.org),
Committee on Publication Ethics (COPE; http://www.
publicationethics.org), World Association of Medical
Editors (WAME; http://wame.org), and European
Association of Science Editors (EASE; www.ease.org.uk)
and request authors to meet these guidelines in submit-
ting their manuscripts. For clinical trials, this journal
requires registration in a public trials registry also.
The Editor-in-Chief and the journal DARU are
members of these three ethical organizations. The jour-
nal is a favorite of many researchers in the field of phar-
macy and has been free to all readers in the world since
its launch. Initiatives to extend the reach of the journal
to readers outside the academic community, framed by
DARU policy to promote the discipline of drug fields
have been successful, judged by rate of highly cited
papers and contribution of scientists in different fields
from various departments. ScopusW data (Figures 1 and
2, Table 1 ) indicate that this journal has had both im-
mediate impact and an enduring quality. The 2011Correspondence: Mohammad.Abdollahi@UToronto.Ca; Mohammad@Tums.Ac.Ir
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In early 2012, DARU moved to Springer BioMed
Central for publication as an Open Access journal.
In the new Open Access model, all articles are freely
and permanently accessible online immediately upon
publication, without subscription charges or its bar-
riers. Authors of articles published in DARU are the
copyright holders of their articles. Following publica-
tion in DARU the full-text of each article is depos-
ited immediately and permanently in repositories in
e-Depot, the National Library of the Netherlands'
digital archive of electronic publications. In Open
Access journals, authors are asked to pay article pro-
cessing charges, of course in DARU, TUMS as the
owner of the journal will pay on behalf of authors
for the first 3 years of its publishing with Springer
BioMed Central and thus all authors are waived in
this period of time.
The editorial policy of this journal is that all sub-
mitted manuscripts are initially examined by the Edi-
tor-in-Chief and if passed initial requirements, then
one of the Section Editors will be assigned to handle
its peer review process. Main initial requirements in-
clude novelty of the study and paper, fitting in scope
of journal, and full adherence to instruction guide-
line and ethical principles.
Statistics for the year 2012 indicates that until May 24,
2012, a total of 272 submissions were received, of which, 73
entered to peer review process, 32 (44%) were accepted and
41 (56%) were rejected. The average review time has been
23 days.
DARU is indexed and abstracted in many abstracting
and indexing databases such as ISI Web of Science,
PubMed Central, Scopus, Excerpta Medica/EMBASE,
Scirus, Directory of Open Access Journals (DOAJ), Bio-
logical Abstracts (BIOSIS), EBSCO, Asian Science Cit-
ation Network (ASCN), CAB Abstracts, Chemical
Abstracts Service (CAS), Free Medical Journals, Global
Health, Google Scholar, HINARI, Index Copernicus,an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Growth of DARU published papers in ScopusW.
Figure 2 Number of citations to DARU published papers in ScopusW.
Table 1 List of top 10 most cited articles according to
Scopus
Reference No. of Citation
Krishna Mohan et al. 2007 [1] 25
Sajjadi 2006 [2] 25
Delazar et al. 2006 [3] 23
Patel et al. 2006 [4] 21
Abdollahi et al. 2008 [5] 17
Miri et al. 2008 [6] 17
Delazar et al. 2004 [7] 16
Khorram Khorshid et al. 2008 [8] 15
Masoompour et al. 2008 [9] 14
Yaghoubi et al. 2007 [10] 14
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http://www.darujps.com/content/20/1/1Index Medicus for WHO Eastern Mediterranean Region
(IMEMR), International Pharmaceutical Abstracts (IPA),
Natural Product Extracts (NAPRALERT), Open J-Gate,
SIR.
Publication as the final important stage of any sci-
entific research is necessary for development of
sciences and knowledge of the world. By publication,
world scientists talk to each other and share their
idea, thoughts, findings, and opinions. The science of
pharmacy is not an exclusive and thus we need all
scientists of the world to consider this journal as one
of their favorite to share their studies with others.
The editorial board and managers of this journal try
their best to develop knowledge and technology in
the field of pharmacy in the globe by adhering higher
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needs of academics, researchers and professionals.
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